Transdermal selegiline (Emsam)
Medical Letter on Drugs and Therapeutics 48(1235): 41-42
2006
ISSN/ISBN: 0025-732X PMID: 16770292 Document Number: 600382
Document emailed within 1 workday
Related Documents
Kramar, M.; Giersch, K.H.; Schneider, H.T. 1987: Transdermal therapy of stable angina pectoris. Comparison of 2 different transdermal systems Fortschritte der Medizin 105(17): 340-342Dittrich, R.; Parker, L.; Rosen, J.B.; Shangold, G.; Creasy, G.W.; Fisher, A.C. 2002: Transdermal contraception: Evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study American Journal of Obstetrics and Gynecology 186(1): 15-20
Dittrich, R.; Parker, L.; Rosen, J.B.; Shangold, G.; Creasy, G.W.; Fisher, A.C. 2002: Transdermal contraception: Evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study American Journal of Obstetrics and Gynecology 186(1): 15-20
Szatmári, I.; Tóth, K. 1992: Pharmacokinetics and metabolism of selegiline Acta Pharmaceutica Hungarica 62(5): 243-248
Simon, K.; Böcskei, Z.; Török, Z. 1992: Study of selegiline and related compounds with x-ray diffraction Acta Pharmaceutica Hungarica 62(5): 225-230
Knoll, J. 2000: (-)Deprenyl (Selegiline): past, present and future Neurobiology 8(2): 179-199
Dixit, S.N.; Behari, M.; Ahuja, G.K. 1999: Effect of selegiline on cognitive functions in Parkinson's disease Journal of the Association of Physicians of India 47(8): 784-786
Csanda, E.; Tárczy, M. 1987: Selegiline in the early and late phases of Parkinson's disease Journal of Neural Transmission. Supplementum 25: 105-113
Louden, M.B.; Morehead, M.A.; Schmidt, H.S. 1995: Activation by selegiline (Eldepryle) of REM sleep behavior disorder in parkinsonism West Virginia Medical Journal 91(3): 101
Kwieciński, H.; Janik, P.; Jamrozik, Z.; Opuchlik, A. 2001: The effect of selegiline and vitamin e in the treatment of ALS: an open randomized clinical trials Neurologia i Neurochirurgia Polska 35(1 Suppl): 101-106
Timár, J. 1989: Recovery of MAO-B enzyme activity after (-)deprenyl (selegiline) pretreatment, measured in vivo Acta Physiologica Hungarica 74(3-4): 259-266
Takács, M.; Vámos, J.; Papp, Q.; Erósné Takácsy, T.; Hegedúsné Vajda, J.; Mikóné, H.Z.; Némethné Palotás, J. 1999: In vitro interaction of selegiline, riboflavin and light. Sensitized photodegradation of drugs. i Acta Pharmaceutica Hungarica 69(3): 103-107
Gerlach, M.; Desser, H.; Youdim, M.B.; Riederer, P. 1996: New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline Journal of Neural Transmission. Supplementum 48: 7-21
Vrana, S.L.; Azzaro, A.J.; Vrana, K.E. 1992: Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway Molecular Pharmacology 41(5): 839-844
Shan, D.E.; Yeh, S.I. 1996: An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl Zhonghua Yi Xue Za Zhi 58(4): 264-268
Aaltonen, H.; Kilkku, O.; Heinonen, E.; Mäki-Ikola, O. 1998: Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality Bmj 317(7172): 1586-1587
Counsell, C. 1998: Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required Bmj 317(7172): 1586
2003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
Niedner, R. 1988: Transdermal therapeutic systems (TTS) Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 39(12): 761-766
Rietbrock, N. 1985: Transdermal application of glyceryltrinitrate Deutsche Medizinische Wochenschrift 110(43): 1673-1674